Vitiligo

Tildrakizumab, HCP-administered biologics, and lifestyle-based decision-making took center stage in an interactive discussion led by Omar Noor, MD, FAAD, and colleagues.

Topical ruxolitinib, phototherapy, and psychosocial care took center stage in an interactive discussion between Seemal Desai, MD, FAAD, and colleagues, on managing complex vitiligo cases.

At a recent Dermatology Times Case-Based Roundtable event, Stephanie Simmerman, DNP, APRN-C, discussed treatment selection, access challenges, and more for patients with vitiligo.

A systematic review reveals significant Treg cell deficiencies in vitiligo, highlighting their role as therapeutic targets for improved treatment strategies.

A recent study reveals distinct patterns of nonsegmental vitiligo lesions on hands.

After 4 months of treatment with the dual therapy, patients with refractory vitiligo exhibited an overall 55% remission rate.

A pilot study evaluates tildrakizumab's safety and potential in treating stable nonsegmental vitiligo, highlighting the need for further research on IL-23 inhibitors.

Discover the latest advancements in vitiligo treatment and awareness as Dermatology Times highlights this year's progress during Vitiligo Awareness Month.

The VALIANT survey uncovers alarming depression rates in vitiligo patients, highlighting the urgent need for improved mental health screenings and interventions.

Discover promising advancements in vitiligo treatments, including innovative therapies and combination approaches that enhance skin repigmentation and improve patient quality of life.

Recent research outlined 5 subtypes of vitiligo that can be used to guide therapeutic choices.

At a recent Dermatology Times Case-Based Roundtable event, Michael Gold, MD, explored innovative vitiligo treatment strategies through complex cases and emerging therapies.

New research reveals significant racial disparities in depression risk among vitiligo patients, highlighting the need for culturally sensitive mental health support.

Discover the promising efficacy and safety of combining platelet-rich plasma with fractional laser therapy for treating vitiligo in adults.

Combining tofacitinib with UVB therapy significantly enhances vitiligo treatment outcomes, improving recovery rates and quality of life for patients.

Clinuvel's phase III trial CUV105 enrolls 200 patients, exploring afamelanotide as a promising systemic treatment for vitiligo.

Explore the promising role of JAK inhibitors in vitiligo management, highlighting efficacy, safety, and potential combination therapies for enhanced results.

Genetic proxies for PCSK9 inhibition were consistently associated with reduced vitiligo risk across 2 biobanks.

Phototherapy, commonly used for vitiligo, might help reduce cardiovascular risk through anti-inflammatory effects.

Corticosteroids, calcineurin inhibitors, and fractional CO2 laser were also effective in achieving high levels of repigmentation.

The significance of patient education and setting realistic expectations for the often-slow process of repigmentation in vitiligo treatment was a key focus of the discussion.

Compared to patients with rheumatoid arthritis and atopic dermatitis, those with vitiligo had a lower incidence of major adverse effects.

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

The analyzed dataset included over 200,000 patients with vitiligo to find trends in diagnosis, treatment, and more.

Serota and other field experts discussed best practices as well as new therapeutics.